Intermittent endocrine treatment

World Journal of Urology

Volumn 18, Issue 3, 2000, Pages 183-189

  Van Cangh, Paul J ^a   Tombal, Bertrand ^a   Gala, Jean Luc ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

AGED; CASE REPORT; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; MALE; PROSTATE TUMOR; REVIEW;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0034207921     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003459900101     Document Type: Article

References (21)

1. Abi Aad AS, Van Cangh PJ (1996) Intermittent androgen therapy. Acta Urol Belg 64: 91-92
2. Akakura K. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL. Tenniswood M, Fox K (1996) Effects of intermittent androgen suppression on the stern cell composition and the expression of TPRM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 59: 501-511
3. Belldegrun A, McBride W. Tso CL (1999) Hormone deprivation treatment induces selective growth of super aggressive prostate cancer clones (abstract 483). J Urol 161 [Suppl]: 127
4. Crook JM. Szumacher E, Malone S, Huan S, Segal R (1999) Intermittent androgen suppression in the management of prostate cancer. Urology 53: 530-534
5. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P (1998) Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1: 289-296
6. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839-844
7. Goldenberg SL, Gleave ME, Bruchovsky N (1999) The role of intermittent androgen suppression in prostate cancer. AUA Update Ser 18: 18-23
8. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N (1999) Clinical experience with intermittent androgen suppression in prostate cancer. Mol Urol 3: 287-292
9. Grossfeld GD, Small EJ, Carroll PR (1998) Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 51: 137-144
10. Higano CS, Ellis W, Rüssel K, Lange PH (1996) Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48: 800-804
11. Horwich A. Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P (1998) A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 81: 96-99
12. Isaacs JT (1999) The biology of hormone refractory prostate cancer. Urol Clin North Am 26: 263-273
13. Klotz LH, Herr HW, Morse MJ, Whitmore WE (1986) Intermittent endocrine therapy for advanced prostate cancer. Cancer 58: 2546-2550
14. Nejat RJ, Rashid HH, Choi J, Noble CB, Fagelman E, Katz AE, Benson MC (1999) Time to normalization of serum testosterone levels after withdrawal of androgen deprivation therapy (abstract 1311). J Urol 161 [Suppl]: 339
15. Noble RL ( 1977) Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37: 82-94
16. Oliver RT, Williams G, Paris AM, Blandy JP (1997) Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49: 79 82
17. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH. Sullivan LD (1996) Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 58: 139-146
18. Theyer G, Hamilton G (1998) Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 52: 353-359
19. Vahlensieck W, Wegner G, Lehman HD, Franzen G, Steifen L, Wählby S (1985) Comparison between continuous and intermittent administration of Estracyt in the treatment of carcinoma of the prostate. Urol Res 13: 209-212
20. Van Cangh PJ (1997) How to handle the patient with a rising PSA level (all stages). In: Schröder FH (ed) Recent advances in prostate cancer and BPH. Parthenon, New York, London, pp 261-272
21. Zerbib M, Conquy S (1997) Le traitement hormonal intermittent dans le cancer de la prostate. Progr Urol 7: 1026-1027